Back to blog
April 13, 2026 · 9-Lens Analysis · Earnings Preview

Morgan Stanley Q1 2026 Preview: Record Wealth Franchise, 300bps Excess Capital, and Every Executive Sold Into the Peak

Morgan Stanley delivered record FY2025 results — $70.6B revenue, $10.21 EPS, 21.6% ROTCE, and three consecutive quarters of fee-based wealth flows above $40B (a first for the industry). Then every named Section 16 officer filed a discretionary Form 144 and sold into the $181-186 post-earnings window. A 9-lens preview ahead of Q1 earnings this week.

The Setup

FY25 Revenue
$70.6B

Record, +~16% YoY

FY25 EPS
$10.21

Record; 21.6% ROTCE

CET1 Ratio
15.0%

~300bps above minimum

Client Assets
$9.3T

+$1.4T YoY

Morgan Stanley enters Q1 2026 from a position of operational strength. Every first-order lens in our 9-lens committee identified durable franchise advantages, a strong capital position, and no material accounting or regulatory red flags. The Wealth Management franchise delivered $31.8B in FY25 revenue with $160B of fee-based flows and $356B of net new assets — industry-leading metrics that compound mechanically. Institutional Securities gained 100bps of wallet share and posted record $33.1B with IB up 47% YoY in Q4.

So why is the tone of our assessment cautious? Because three signals cluster around narrative and expectations. CEO Ted Pick has built a "higher plane" framing that is doing real work in the stock price. The capital markets cycle exposure is likely mid-to-late cycle rather than early-cycle. And every named executive sold unanimously into the post-earnings price peak.

The Insider Selling Cluster

Unanimous Section 16 Selling

Between October 31, 2025 and January 30, 2026, every named executive officer of Morgan Stanley filed a discretionary Form 144. Seven of them executed open-market sales on January 20, 2026 in the $181-186 range. Pick separately filed a 100,000 share notice at approximately $164 on October 31. None were 10b5-1 pre-planned — all were discretionary.

ExecutiveRoleSharesProceeds
Ted Pick (Form 144 only)CEO / Chairman100,000~$16.4M
Daniel SimkowitzCo-President32,968$6.0M
Andrew SapersteinCo-President30,330$5.6M
Eric GrossmanChief Legal/Admin Officer21,555$4.0M
Michael Pizzi TrustHead Tech & Ops20,000$3.7M
Sharon YeshayaCFO15,838$2.9M
Charles SmithChief Risk Officer8,500$1.5M
Mandell CrawleyChief Client Officer7,860$1.4M

Executives retain substantial holdings — Pick over 700K shares, Saperstein over 290K, Simkowitz over 390K. This is rebalancing, not exit. But the unanimity is the signal. Individual sales are defensible as routine post-earnings window rebalancing; eight Section 16 officers selecting the same window at the same price level, labeled discretionary rather than 10b5-1, is a materially different pattern. The stock peaked near $186 shortly after these sales and declined to $160.89 by March 12, when the next PSU vesting event occurred — a 13% drawdown from the selling window.

The "Higher Plane" Narrative

Pick has deliberately built a narrative around earnings durability and "higher lows" through cycle. He explicitly refused to raise firm-wide targets on the Q4 call despite hitting them, framing it as prudence rather than a ceiling. The "confidence we can generate 17.5% ROTCE with EPS below $8" comment is a rare concrete bear-case floor that also reveals where management wants investors anchored.

Management's Own Caution

Pick's Q4 2025 opening comment flagged "ambulant markets," "higher asset prices," and warned against "overreaching." CEOs rarely warn on their own outlook during record quarters. This is honest communication and also creates narrative fragility — the CEO himself has signaled limits to upside.

Pick also characterized capital markets as in the "third inning" of an upcycle. Base rates for multi-year IB upcycle forecasts are poor — Wall Street has repeatedly called "green shoots" cycles that disappointed. If 2025 turns out to have been a high plateau rather than an early cycle year, consensus 2026-2027 EPS estimates would need to come down 15-25% and the multiple compresses.

What Matters in Q1 2026

1. IB revenue trajectory. Q4 posted 47% YoY growth — a high bar. Sub-20% growth would be consistent with mid-cycle normalization rather than the "third inning" narrative. Sub-10% would break the cycle-is-young thesis.
2. Wealth margin ex-DCP. Q4 reported 31.4% with DCP impact of 95 basis points. The Q1 2026 DCP hedging transition adds transitional costs. Can the adjusted margin hold 30%+?
3. NII trajectory. Guidance was flat Q1 then rising. Deposit mix and loan growth are the swing factors.
4. Buyback pace. $1.5B in Q4 implies $6B annualized. With 300bps excess capital on roughly $260B of market cap, acceleration would signal management confidence in valuation. Deceleration would signal caution.
5. Pipeline commentary tone. "Healthy global diversified" is the current phrase. Any softening would be the leading indicator of cycle normalization.

The Compound Scenario Worth Naming

Our Black Swan Beacon lens ran because of the narrative-driven trigger criterion, and the most likely adverse scenario it identified is not a fundamental failure. It is narrative derating without fundamental failure — Q1 or Q2 results that, while operationally fine, simply fail to clear the "compound through cycle" bar, driving multiple compression from roughly 15x forward to 12x and a 20-25% stock drawdown even without an EPS revision. Probability moderate, severity significant but survivable. Buyback absorption provides a partial floor.

The prime brokerage tail risk is structurally real but low-probability. Record client balances at cycle peaks historically correlate with future drawdowns, and an Archegos-style counterparty event remains the principal idiosyncratic tail exposure. MS has rebuilt its risk framework post-2021 and the 300bps capital buffer provides absorption, but the exposure cannot be eliminated given the business model at scale.

The Full Committee Analysis

Our complete 9-lens analysis of Morgan Stanley covers the Wealth Management moat, Institutional Securities wallet share gains, capital deployment discipline, regulatory posture, the executive selling cluster in detail, accounting integrity, and the tail risk framework. It is available on the equity analysis page.

View the full Morgan Stanley analysis

This report was generated by the Runchey Research AI Ensemble using primary SEC data and reviewed by Matthew Runchey for accuracy.

This analysis is for educational purposes only and does not constitute investment advice. See our Editorial Integrity & Disclosure Policy and Terms of Service.